CASC
PBE icon

Coppell Advisory Solutions Corp’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Coppell Advisory Solutions Corp’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13
Closed -$825 – 801
2022
Q4 		$825 Buy
+13
New +$825 ﹤0.01% 955

Other funds holding PBE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
YIA
YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return
CW
CreativeOne Wealth Overland Park, Kansas $4.31B AUM 19.42% 1-Year Est. Return

Coppell Advisory Solutions Corp's PBE Position: Q1 2023 in Review

Coppell Advisory Solutions Corp sold out of Invesco Biotechnology & Genome ETF (PBE) in Q1 2023, closing a stake of 13 shares — an estimated $825 sold.

Coppell Advisory Solutions Corp first reported a position in PBE in Q4 2022 and held it in 1 quarter. The position peaked at $825 in Q4 2022. 101 funds tracked by Wall St. Rank hold PBE as of Q1 2023.

  • Coppell Advisory Solutions Corp reported no remaining Invesco Biotechnology & Genome ETF position as of Q1 2023 after selling out during the quarter.
  • Coppell Advisory Solutions Corp sold 13 Invesco Biotechnology & Genome ETF shares in Q1 2023, an estimated $825.
  • Coppell Advisory Solutions Corp first reported a position in Invesco Biotechnology & Genome ETF in Q4 2022 and held it in 1 quarter.
  • Coppell Advisory Solutions Corp's Invesco Biotechnology & Genome ETF position peaked at $825 in Q4 2022.
  • 101 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2023.

Based on Coppell Advisory Solutions Corp's 13F filing for Q1 2023, filed 10 May 2023.